Industry Braces For More Pressure On IP For COVID-19 Products
The controversial “TRIPS waiver” is high on the agenda of the World Trade Organization’s upcoming ministerial conference, while a working group of the World Health Organization is drawing up a draft pandemic treaty that includes proposals to weaken IP on pandemic countermeasures.
You may also be interested in...
Coronavirus Notebook: Moderna Postpones EU Spikevax Supplies, Industry Insists TRIPS Waiver Is Redundant
The medical NGO, MSF, has urged countries not to adopt the latest draft of the proposed waiver, saying it would impair efforts to boost access to COVID-19 products around the world. The WHO has been looking at the benefits of hybrid immunity – and how far it might be waning.
The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.
Experiences during the COVID-19 pandemic are expected to help identify future opportunities for regulatory cooperation on real-world evidence and avoid divergent decision-making for products including advanced therapies and personalized medicines.